Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 35.60 INR
Change Today 0.00 / 0.00%
Volume 0.0
NLSC On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

nectar lifesciences ltd (NLSC) Snapshot

Open
35.85
Previous Close
35.45
Day High
36.40
Day Low
35.25
52 Week High
09/16/14 - 44.70
52 Week Low
08/13/14 - 24.55
Market Cap
8.0B
Average Volume 10 Days
843.2K
EPS TTM
2.95
Shares Outstanding
224.3M
EX-Date
--
P/E TM
12.1x
Dividend
0.10
Dividend Yield
0.28%
Current Stock Chart for NECTAR LIFESCIENCES LTD (NLSC)

Related News

No related news articles were found.

nectar lifesciences ltd (NLSC) Related Businessweek News

No Related Businessweek News Found

nectar lifesciences ltd (NLSC) Details

Nectar Lifesciences Limited, an integrated pharmaceutical company, primarily manufactures various active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and Chiral resolution; and chemical and analytical development, and analytical and manufacturing services, as well as engineering consulting services. Its APIs and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime hcl, cephalothin, cefazolin sodium cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspension, and granules and injectibles. In addition, the company offers generic and OTC products for various therapeutic areas; a range of diagnostics products; empty hard gelatin capsules; and manufactures menthol and allied products, including menthol crystals, menthol flakes, peppermint oil, cis 3 hexenol, mentha piperita, Indian spearmint oil, menthones, mint blends, dementholised peppermint oil, and other customized mint based products. The company was incorporated in 1995 and is headquartered in Chandigarh, India.

Founded in 1995

nectar lifesciences ltd (NLSC) Top Compensated Officers

Chief Executive Officer and Wholetime Directo...
Total Annual Compensation: 6.5M
Chairman, Managing Director, Member of Share ...
Total Annual Compensation: 7.6M
President of Operations and Wholetime Directo...
Total Annual Compensation: 2.3M
Compensation as of Fiscal Year 2014.

nectar lifesciences ltd (NLSC) Key Developments

Nectar Lifesciences Limited Announces Audited Standalone Earnings Results for the Fourth Quarter and Year Ended and Audited Consolidated Earnings Results for the Year Ended March 31, 2015

Nectar Lifesciences Limited announced audited standalone earnings results for the fourth quarter and year ended and audited consolidated earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company's net sales were INR 4,234.6 million compared with INR 4,604.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 364.9 million compared with INR 539.8 million a year ago. Profit from ordinary activities before tax was INR 224.4 million compared with INR 219.2 million a year ago. Net profit was INR 167.1 million or INR 0.75 per basic and diluted share compared with INR 186.9 million or INR 0.83 per basic and diluted share a year ago. For the year, on standalone basis, the company's net sales were INR 16,428.9 million compared with INR 16,377.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,903.4 million compared with INR 2,045.8 million a year ago. Profit from ordinary activities before tax was INR 847.5 million compared with INR 782.2 million a year ago. Net profit was INR 662.6 million or INR 2.95 per basic and diluted share compared with INR 620.8 million or INR 2.77 per basic and diluted share a year ago. For the year, on consolidated basis, the company's net sales were INR 16,423.9 million compared with INR 16,377.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,903.4 million compared with INR 2,045.8 million a year ago. Profit from ordinary activities before tax was INR 847.5 million compared with INR 782.2 million a year ago. Net profit was INR 662.6 million or INR 2.95 per basic and diluted share compared with INR 620.8 million or INR 2.77 per basic and diluted share a year ago.

Nectar Lifesciences Limited Recommends Final Dividend for the Financial Year 2014-2015

Nectar Lifesciences Limited has informed that Pursuant to the Board of Directors in their meeting held on May 29, 2015 have recommended the 10% final dividend i.e. INR 0.10 per equity share to the members of the company, out of profits of the company for the financial year 2014-2015, subject to the approval of the members in their Annual General Meeting.

Nectar Lifesciences Limited to Report Fiscal Year 2015 Results on May 29, 2015

Nectar Lifesciences Limited announced that they will report fiscal year 2015 results on May 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLSC:IN 35.60 INR 0.00

NLSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLSC.
View Industry Companies
 

Industry Analysis

NLSC

Industry Average

Valuation NLSC Industry Range
Price/Earnings 9.6x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 4.4x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NECTAR LIFESCIENCES LTD, please visit www.neclife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.